Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
153
-
Total 13F shares, excl. options
-
48M
-
Shares change
-
-555K
-
Total reported value, excl. options
-
$1.84B
-
Value change
-
-$63.2M
-
Put/Call ratio
-
0.7
-
Number of buys
-
74
-
Number of sells
-
-74
-
Price
-
$38.26
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q1 2023
196 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2023.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 153 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48M shares
of 80M outstanding shares and own 59.99% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (3.81M shares), Skorpios Trust (3.27M shares), ALKEON CAPITAL MANAGEMENT LLC (3.22M shares), BlackRock Inc. (2.78M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.62M shares), Avidity Partners Management LP (2.45M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.39M shares), BAKER BROS. ADVISORS LP (2.37M shares), STATE STREET CORP (2.23M shares), and VANGUARD GROUP INC (2.14M shares).
This table shows the top 153 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.